Magnus Grönberg, Author at Inify Laboratories

Notice to Extraordinary General Meeting in Inify Laboratories AB (publ)

Annual General Meeting, Investor News 2022-07-28

STOCKHOLM – July 28, 2022 – Inify Laboratories AB (publ) hereby invites its shareholders to en Extraordinary General Meeting on August 30th, 2022. Please find attached the invitation including agenda […]

Kallelse till extra bolagsstämma i Inify Laboratories AB (publ)

Uncategorized 2022-07-28

STOCKHOLM – 28 juli, 2022 – Inify Laboratories AB (publ) kallar härmed sina aktieägare till en extra bolagsstämma den 30:e augusti 2022. Bifogat finns kallelse inklusive dagordning och instruktioner för registrering […]

Notice to Extraordinary General Meeting in Inify Laboratories AB (publ)

Annual General Meeting, Investor News 2022-07-28

Inify Laboratories announces the appointment of Chief Medical Officer (CMO)

Investor News 2022-06-29

Stockholm, June 29th 2022 Inify Laboratories announces the addition of specialized medical competence to the company’s management team and organization. “We warmly welcome Dr. Claes Lind to the role as […]

Inify Laboratories – now listed on Euronext Growth in Oslo under the INIFY ticker

Investor News 2022-06-20

“Today I’m truly thrilled to announce that Inify Laboratories is admitted to trading on Euronext Growth Oslo, less than 5 months after we became independent. With solid funding of NOK […]

Inify Laboratories AB becomes an independent company

Home, Investor News, News 2021-12-10

STOCKHOLM – December 10, 2021 – ContextVision, a medical technology software company specializing in image processing, today announces that at the EGM of ContextVision on Dec 10th, it was resolved […]

ContextVision to focus pathology efforts on the establishment of a fully AI-supported lab service

Home, Investor News, News 2021-11-15

ContextVision today announces that the Board of Directors of ContextVision has decided to make a strategic shift and focus its pathology business unit entirely on the establishment of an AI based pathology lab service.

Aiming to build the company’s first modern pathology lab

Financial reports, Home, Investor News, News 2021-10-21

ContextVision has decided to build its first fully digital pathology laboratory – thus confirming its strong dedication to advancing digitalization within pathology, for the best of both patients and the medical profession.

INIFY Prostate® shown to accurately outline suspicious prostate cancer in study with two prominent medical centers

Home, News 2021-10-18

ContextVision today announced that results from a US clinical evaluation were presented at the Pathology Visions Congress in Las Vegas, USA.

In the Pan-European multicenter clinical study FirstPath, INIFY Prostate produced highly accurate, robust and homogenous results at all sites

Home, News 2021-08-31

STOCKHOLM – August 31, 2021 – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today announced that results from FirstPath […]

Notice to Extraordinary General Meeting in Inify Laboratories AB (publ)

Kallelse till extra bolagsstämma i Inify Laboratories AB (publ)

Notice to Extraordinary General Meeting in Inify Laboratories AB (publ)

Inify Laboratories announces the appointment of Chief Medical Officer (CMO)

Inify Laboratories – now listed on Euronext Growth in Oslo under the INIFY ticker

Inify Laboratories AB becomes an independent company

ContextVision to focus pathology efforts on the establishment of a fully AI-supported lab service

Aiming to build the company’s first modern pathology lab

INIFY Prostate® shown to accurately outline suspicious prostate cancer in study with two prominent medical centers

In the Pan-European multicenter clinical study FirstPath, INIFY Prostate produced highly accurate, robust and homogenous results at all sites

Our services

Inify Laboratories

For Investors

Contact us

Social media